These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 1397746)

  • 21. Medical treatment of gastro-oesophageal reflux disease.
    De Giorgi F; Savarese MF; Atteo E; Leone CA; Cuomo R
    Acta Otorhinolaryngol Ital; 2006 Oct; 26(5):276-80. PubMed ID: 17345932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.
    Tonini M; De Giorgio R; De Ponti F
    Drugs; 2004; 64(4):347-61. PubMed ID: 14969571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease.
    Howden CW; Burget DW; Hunt RH
    Scand J Gastroenterol Suppl; 1994; 201():79-82. PubMed ID: 8047830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease?
    Hendel J; Hendel L; Aggestrup S
    Aliment Pharmacol Ther; 1995 Dec; 9(6):693-7. PubMed ID: 8824658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease.
    Frazzoni M; De Micheli E; Savarino V
    Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1091-8. PubMed ID: 14653828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Symptoms and disease severity in gastro-oesophageal reflux disease.
    Galmiche JP; Bruley des Varannes S
    Scand J Gastroenterol Suppl; 1994; 201():62-8. PubMed ID: 8047826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Roles of gastric acid and pH in the pathogenesis of gastro-oesophageal reflux disease.
    Dent J
    Scand J Gastroenterol Suppl; 1994; 201():55-61. PubMed ID: 8047825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.
    Gardner JD; Sloan S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1381-6. PubMed ID: 15606401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
    Robinson M
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():30-7. PubMed ID: 15496216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis.
    Katz PO; Ginsberg GG; Hoyle PE; Sostek MB; Monyak JT; Silberg DG
    Aliment Pharmacol Ther; 2007 Mar; 25(5):617-28. PubMed ID: 17305763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.
    Malfertheiner P; Lind T; Willich S; Vieth M; Jaspersen D; Labenz J; Meyer-Sabellek W; Junghard O; Stolte M
    Gut; 2005 Jun; 54(6):746-51. PubMed ID: 15888776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving health-related quality of life in gastro-oesophageal reflux disease.
    Shaw MJ; Crawley JA
    Drugs; 2003; 63(21):2307-16. PubMed ID: 14524732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological targets in gastro-oesophageal reflux disease.
    Piche T; Galmiche JP
    Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):333-41. PubMed ID: 16364047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between the mechanism of gastro-oesophageal reflux and oesophageal acid exposure in patients with reflux disease.
    Scheffer RC; Wassenaar EB; Herwaarden MA; Holloway RH; Samsom M; Smout AJ; Akkermans LM
    Neurogastroenterol Motil; 2005 Oct; 17(5):654-62. PubMed ID: 16185303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Appropriate acid suppression in the treatment of acid-related conditions.
    Howden CW
    Pharmacol Ther; 1994; 63(1):123-34. PubMed ID: 7972343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
    Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing gastro-oesophageal reflux disease in children.
    Cezard JP
    Digestion; 2004; 69 Suppl 1():3-8. PubMed ID: 15001829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: is stringent control of gastric pH useful and practical in GERD?
    Kahrilas PJ
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():89-94; discussion 95-6. PubMed ID: 15456470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between gastric pH and gastro-oesophageal reflux contents: ambulatory pH-impedance monitoring results.
    Roman S; Serraj I; Damon H; Mion F
    Neurogastroenterol Motil; 2007 Jul; 19(7):562-8. PubMed ID: 17593137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.